Background
==========

The Protein Structure Factory
-----------------------------

The Protein Structure Factory (PSF) is a joint endeavour of universities, research institutes and companies from the Berlin area \[[@B1],[@B2]\]. It takes part in the international structural genomics initiative \[[@B3],[@B4]\] and aims at the determination of human protein structures by X-ray diffraction methods and NMR spectroscopy using standardised high-throughput procedures. A complete pipeline has been established for this purpose that comprises cloning, protein expression in small and large scale, biophysical protein characterisation, crystallisation, X-ray diffraction and structure calculation.

It is known that eukaryotic proteins are often difficult to express in *Escherichia coli*\[[@B5]\]. Only a certain fraction of these proteins can be overproduced in *E. coli*in sufficient yield without formation of inclusion body aggregates or proteolytic degradation. Alternative expression systems include cell cultures of various eukaryotic organisms and cell-free, *in vitro*protein expression. These systems have been greatly improved since 1999, when the PSF project was initiated. In the meantime, *E. coli*\[[@B5]-[@B7]\] and wheat germ \[[@B8]\]*in vitro*protein synthesis is routinely used by structural genomics projects. At the PSF, yeast expression hosts, *Saccharomyces cerevisiae*and *Pichia pastoris*, were successfully established as alternative systems to *E. coli*, as described in detail previously \[[@B9]-[@B11]\]. We will focus here on the results obtained with the *E. coli*expression system.

*E. coli*strains and vectors
----------------------------

The T7 RNA polymerase-dependent *E. coli*expression vector system (pET-vectors) is a universal system to generate recombinant protein for structural analysis \[[@B12]\]. pET vectors are usually combined with the *E. coli*B strain BL21 and derivatives that are engineered to carry the T7 RNA polymerase gene. These strains, however, have limitations in cloning and stable propagation of the expression constructs. Expression vectors which are regulated by the *lac*operator are independent of the host strain. Recombination-deficient *E. coli*K-12 strains are suitable for cloning because of their high transformation rates and because they allow for stable propagation of recombinant constructs. The strain SCS1 (Stratagene; *hsd*R17(r~K~^-^m~K~^+^) *recA1 endA1 gyrA96 thi-1 relA1 supE44*) was found to perform well at the PSF in cloning experiments. It grows relatively fast and allows for robust protein expression.

Affinity tags allow for standardised protein purification procedures. The first vector that was used routinely in the PSF, pQStrep2 (GenBank [AY028642](AY028642), Figure [1](#F1){ref-type="fig"}), is based on pQE-30 (Qiagen) and adds an N-terminal His-tag \[[@B13]\] for metal chelate affinity chromatography (IMAC) and a C-terminal Strep-tag II \[[@B14],[@B15]\] to the expression product. pQStrep2 allows for an efficient two-step affinity purification of the encoded protein, as demonstrated in a study of an SH3 domain \[[@B16]\]. The eluate of the initial IMAC is directly loaded onto a Streptactin column. Thereby, only full-length expression products are purified and degradation products are removed. However, the two tags, which are flexible unfolded peptides, remain on the protein and may interfere with protein crystallisation, although we could show that crystal growth may be possible in their presence even for small proteins \[[@B16]\]. To exclude any negative influence by the affinity tags, another vector, pQTEV (GenBank [AY243506](AY243506), Figure [1](#F1){ref-type="fig"}), was constructed. pQTEV allows for expression of N-terminal His-tag fusion proteins that contain a recognition site of the tobacco etch virus (TEV) protease for proteolytic removal of the tag.

![**Vector maps.**Vector maps of pQStrep2, pQTEV and pSE111](1475-2859-4-21-1){#F1}

Codon usage has a major influence on protein expression levels in *E. coli*\[[@B17]\], and eukaryotic sequences often contain codons that are rare in *E. coli*. Especially the arginine codons AGA and AGG lead to low protein yield \[[@B18]\]. This can be alleviated by introducing genes for overexpression of the corresponding tRNAs into the *E. coli*host cells. We have used the plasmid pSE111 (Figure [1](#F1){ref-type="fig"}) carrying the *argU*gene for this purpose. pSE111 is compatible with pQTEV and other common expression vectors. It carries the *lacI*^Q^gene for overexpression of the Lac repressor, which is required when using promoters regulated by *lac*operators. pSE111 was used at the PSF in combination with the expression vectors pQStrep2 and pGEX-6P-1. Strains for overexpression of rare tRNAs are available from Invitrogen (BL21 Codon Plus) and Novagen (Rosetta). The Rosetta strain contains the chloramphenicol-resistant pRARE plasmid that supplies tRNAs for the codons AUA, AGG, AGA, CUA, CCC, GGA \[[@B19]\]. This plasmid is used at the PSF in combination with pQTEV and pGEX-6P-2.

The Additional file [1](#S1){ref-type="supplementary-material"} psfClones.xml lists the vector and helper plasmid for overexpression of rare tRNAs that was used for each individual clone.

Selection of target proteins
----------------------------

We selected target proteins with higher-than-average chances of successful expression in *E. coli*and crystallisation \[[@B1]\]. Proteins were excluded for which sequence analysis predicted that structure determination would be difficult. Starting from the complete set of known human proteins, potentially difficult target proteins and proteins of known structure were excluded according to the following criteria:

• Membrane proteins are known to be complicated targets for structure determination and were excluded. Membrane proteins were identified with the program TMHMM \[[@B20],[@B21]\].

• Since very large proteins are often difficult to express, the maximal length of target proteins was set to 500 amino acids.

• Protein regions that are unstructured or only partially structured \[[@B22]\] may lead to difficulties during protein expression and purification. Unstructured regions are susceptible to proteolyic attack, and represent an obstacle to protein crystallisation. A large proportion of intrinsically unstructured protein sequences are characterised by sequence stretches of low complexity and tandem repeats \[[@B23]\]. Proteins with low complexity regions of more than 20 amino acids length, detected by the SEG program, or with more than one region were excluded \[[@B24],[@B25]\].

• Coiled-coil proteins were excluded from our target list, since this fold is not novel, and structural analysis of coiled coils requires special attention. Many coiled coil proteins form hetero-complexes with other coiled-coil proteins and cannot be studied without their binding partner. Coiled-coils domains are long, extended structures which can usually only be crystallised as domains, i.e. expression constructs lacking other domains have to be prepared. To identify coiled-coil proteins, the program COILS was used \[[@B26]-[@B28]\].

• The cellular localisation of target proteins was assigned with the Meta_A(nnotator) \[[@B29],[@B30]\]. Target proteins annotated to be localised in the extracellular space, endoplasmic reticulum, Golgi stack, peroxisome or mitochondria were excluded from expression in *E. coli*. Many of these proteins require formation of disulphide bonds for correct folding, but these are generally not formed in the reducing environment of the *E. coli*cytoplasm. Therefore, these proteins were allocated only for extracellular expression by yeast host cells. Proteins with predicted intracellular localisation or which were not assigned with a localisation by Meta_A(nnotator) were expressed in the cytosol of *E. coli*.

• Potential target proteins were matched to the sequences of proteins with known structure at the Protein Data Bank (PDB) \[[@B31]\]. PSI-BLAST \[[@B32]\] was used to detect even very distinct homologies to PDB entries to rule out proteins with known folds. This filter was later replaced by a less stringent one, which considers the sequence identity and \'coverage\' of matches to PDB sequences. The coverage is the length of the sequence match divided by the protein length. According to the less stringent filter, proteins with 60% or more sequence identity over 90% or more of the sequence length were excluded. Thereby target proteins could be included of which only a part, e.g. a single domain, has a known structure.

Results
=======

Target lists
------------

The first target list was generated in 1999, when the PSF project started, from the set of all human proteins known at that time. This set was filtered as described above. PSI-BLAST was used to match potential target proteins to the PDB and to include only proteins of presumably novel folds. To enable high-throughput cloning, we selected target proteins for which full-length cDNA clones were available. In 1999, cDNA clones of the IMAGE consortium represented the main public source of sequenced cDNA clones \[[@B33]\]. However, only partial sequence information existed for these clones -- the EST sequences of the dbEST database \[[@B34]\] -- and only a small proportion contained complete open reading frames (full-ORF clones). 490 proteins were selected which met the selection criteria, had no match to PDB detected by PSI-BLAST and for which full-ORF IMAGE cDNA clones were available.

In 2003, a second target list was compiled from novel full-length cDNAs discovered by the German cDNA consortium \[[@B35],[@B36]\]. The same filter criteria as for the first target list were applied, except that cellular localisation was not taken into account. Proteins with a PDB match of 60% or more sequence identity and 90% sequence coverage were excluded, resulting in a target list of 259 proteins.

A third set of target proteins was selected from a human cDNA expression library (hEx1), which was cloned in a bacterial expression vector. This library was screened for expression clones on high density arrays and by high-throughput protein expression and purification experiments \[[@B37]-[@B40]\]. This identified 2,700 clones expressing soluble His-tag fusion proteins that could be purified by affinity chromatography \[[@B39]\]. The cDNA inserts of these clones were sequenced and assigned to sequences of the Ensembl database \[[@B41]\]. 141 proteins represented by clones of the expression library where selected as targets for structural analysis \[[@B39]\]. These clones express soluble, full-length proteins, of which the three-dimensional structure was unknown.

The numbers of targets and success rates grouped by the type of target cDNA clone are summarised in Table [1](#T1){ref-type="table"}.

###### 

Origin of template cDNA clones Numbers of targets grouped by type of template cDNA clone

  Target list            Number of targets   Number of successfully cloned cDNA   Number of proteins with soluble expression   Number of structures
  ---------------------- ------------------- ------------------------------------ -------------------------------------------- ----------------------
  1 -- IMAGE clones      490                 264                                  54                                           3
  2 -- cDNA consortium   259                 185                                  34                                           2
  3 -- hEx1 library      141                 88                                   51                                           3
                                                                                                                               
  all                    890                 537                                  139                                          8

Generation and characterisation of expression clones
----------------------------------------------------

We established a common cloning strategy that allows for easy shuttling of cDNA fragments between different *E. coli*and yeast vectors. We adopted a cloning system that adds only a minimal number of extra amino acids to the protein of interest and therefore decided to clone with restriction enzymes instead of using alternative systems, such as Invitrogen\'s Gateway system or ligation independent cloning \[[@B42]\].

The PSF has been working with more than a thousand target proteins to date. Suitable cDNA clones were selected and subcloned into the *E. coli*expression vectors pQTEV GenBank [AY243506](AY243506) and pQStrep2 [AY028642](AY028642)\[[@B16]\]. These vectors provide for an N-terminal His-tag; pQStrep2 also encodes an C-terminal Strep-tag-II. Some proteins have also been expressed as GST fusion proteins using the vectors pGEX-4T2 or pGEX-6P1 (Amersham Biosciences).

Expression of protein coding genes from multiple transformants per target was tested under multiple conditions. Standardisation and automation was introduced to achieve this throughput. Expression clones were characterised by small scale protein synthesis at different temperatures, 37°C, 30°C and 25°C, in 1 ml volumes in deep-96-well microplates. Proteins were purified in parallel by a pipetting robot, as described previously \[[@B43]\]. 10% of the purified protein eluate from a 1 ml culture was analysed by SDS-PAGE. For each protein expression experiment, the size of the expression product was recorded and the amount of protein was classified into four categories: none, weak, moderate and strong expression. This classification is arbitrary to a certain degree, however, we found it sufficient to select suitable clones for protein production scale-up.

1414 clones for 537 target proteins were successfully cloned in *E. coli*expression vectors, with 473, 191 and 94 target proteins corresponding to target lists one (IMAGE clones), two (DKFZ clones) and three (hEx1 clones), respectively. Clones for 139 different target proteins were found to be expressed in soluble form by *E. coli*. Figure [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"} show the result of small scale expression and purification of these proteins. The yield varied significantly among different target proteins. The Additional file [1](#S1){ref-type="supplementary-material"} psfClones.xml contains further details on the expression clones, such as vector, strain and helper plasmid for overexpression of rare tRNAs.

![**SDS-PAGE of purified human proteins.**15% SDS-PAGE (Coomassie-stained) of proteins expressed in small scale in *E. coli*and purified by automated immobilised metal chelate affinity chromatography as described in \[43\]. The identities of the purified proteins are indicated in Table 2. Protein expression was induced at the temperature that is optimal for the individual clone. These temperatures are listed in the supplementary file psfClones.xml. M: Molecular weight marker.](1475-2859-4-21-2){#F2}

###### 

PSF *E. coli*expression clones with soluble expression products. The table corresponds to the proteins shown in Figure 2. More detailed information is available in the supplementary XML file, Additional file [1](#S1){ref-type="supplementary-material"}.

  NCBI Entrez gene ID   Gene symbol, name                                                                        Protein accession   RZPD clone ID   Sequence verified, non-silent mutations   Clone accession        Protein size \[Da\]   Protein gel, lane
  --------------------- ---------------------------------------------------------------------------------------- ------------------- --------------- ----------------------------------------- ---------------------- --------------------- -------------------
  39                    ACAT2, acetyl-Coenzyme A acetyltransferase 2                                             AAM00223            PSFEp250C082    partly, none                                                     44,177                D, 24
  203                   AK1, adenylate kinase 1                                                                  BAA78534            PSFEp250B112    yes, none                                 [DQ000549](DQ000549)   24,558                C, 21
  689                   BTF3, basic transcription factor 3                                                       CAA37376            PSFEp758D0224   no                                                               20,622                A, 27
  830                   CAPZA2, capping protein (actin filament) muscle Z-line, alpha 2                          AAC60382            PSFEp758H1226   no                                                               59,649                A, 4
  1036                  CDO1, cysteine dioxygenase, type I                                                       BAA12872            PSFEp758D0124   yes, none                                 [DQ000531](DQ000531)   25,895                E, 16
  1428                  CRYM, crystallin, mu                                                                     AAC16914            PSFEp758B0810   yes, none                                 [DQ000499](DQ000499)   36,275                D, 4
  1460                  CSNK2B, casein kinase 2, beta polypeptide                                                CAA34379            PSFEp758H0422   no                                                               26,209                B, 12
  1606                  DGKA, diacylglycerol kinase, alpha 80kDa                                                 AAC34806            PSFEp758F0324   yes, none                                 [DQ000529](DQ000529)   16,408                A, 23
  1627                  DBN1, drebrin 1                                                                          AAH07567            PSFEp250C052    partly, none                                                     74,354                C, 31
  1635                  DCTD, dCMP deaminase                                                                     AAC37579            PSFEp250B121    yes, none                                 [DQ000535](DQ000535)   22,938                E, 25
  1937                  EEF1G, eukaryotic translation elongation factor 1 gamma                                  AAH15813            PSFEp250H061    partly, none                                                     53,045                C, 11
  1974                  EIF4A2, eukaryotic translation initiation factor 4A, isoform 2                           AAH48105            PSFEp250H052    partly, none                                                     49,301                D, 20
  2963                  GTF2F2, general transcription factor IIF, polypeptide 2, 30 kDa                          CAA42419            PSFEp250B012    yes, none                                 [DQ000547](DQ000547)   31,304                C, 17
  2992                  GYG, glycogenin                                                                          AAB00114            PSFEp758H1122   yes, none                                 [DQ000517](DQ000517)   40,403                B, 4
  3151                  HMGN2, high-mobility group nucleosomal binding domain 2                                  AAA52678            PSFEp250E102    yes, none                                 [DQ000559](DQ000559)   12,314                D, 27
  3312                  HSPA8, heat shock 70 kDa protein 8                                                       BAB18615            PSFEp250E022    partly, none                                                     56,444                D, 31
  3735                  KARS, lysyl-tRNA synthetase                                                              AAH04132            PSFEp250D032    partly, A116G                                                    70,976                D, 16
  3925                  STMN1, stathmin 1/oncoprotein 18                                                         CAC16020            PSFEp250F072    yes, none                                 [DQ000556](DQ000556)   20,225                D, 19
  4043                  LRPAP1, low density lipoprotein receptor-related protein associated protein 1            AAC67373            PSFEp250G031    yes, none                                 [DQ000540](DQ000540)   44,391                C, 22
  4695                  NDUFA2, NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2                            AAD27762            PSFEp250D091    no                                                               13,843                C, 13
  4698                  NDUFA5, NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5                            AAD21526            PSFEp250A0510   no                                                               16,381                A, 13
  5184                  PEPD, peptidase D                                                                        AAH28295            PSFEp250H122    yes, none                                 [DQ000560](DQ000560)                         D, 29
  5202                  PFDN2, prefoldin 2                                                                       AAF17218            PSFEp250D112    yes, none                                 [DQ000555](DQ000555)   19,570                D, 17
  5412                  UBL3, ubiquitin-like 3                                                                   AAD02323            PSFEp758A0510   yes, none                                 [DQ000501](DQ000501)   15,657                
  5502                  PPP1R1A, protein phosphatase 1, regulatory (inhibitor) subunit 1A                        AAB02402            PSFEp758G0124   yes, none                                 [DQ000526](DQ000526)   21,862                A, 15
  5716                  PSMD10, proteasome (prosome, macropain) 26S subunit, non-ATPase, 10 (gankyrin)           AAH11960            PSFEp250A062    yes, none                                 [DQ000544](DQ000544)   27,351                C, 9
  5717                  PSMD11, proteasome (prosome, macropain) 26S subunit, non-ATPase, 11                      AAH04430            PSFEp250B122    yes, none                                 [DQ000548](DQ000548)   50,390                C, 19
  5877                  RABIF, RAB interacting factor                                                            AAB18264            PSFEp250C021    no                                                               16,761                E, 23
  6133                  RPL9, ribosomal protein L9                                                               BAA03401            PSFEp758E0124   yes, none                                 [DQ000524](DQ000524)   24,786                A, 28
  6156                  RPL30, ribosomal protein L30                                                             CAA55820            PSFEp758A1113   yes, none                                 [DQ000503](DQ000503)   15,284                D, 6
  6191                  RPS4X, ribosomal protein S4, X-linked                                                    BC007308            PSFEp758A0923   no                                                               28,670                
  6342                  SCP2, sterol carrier protein 2                                                           AAA03559            PSFEp758C0723   yes, none                                 [DQ000515](DQ000515)   16,668                B, 1
  6451                  SH3BGRL, SH3 domain binding glutamic acid-rich protein like                              AAC27445            PSFEp758C0713   no                                                               15,274                D, 2
  6728                  SRP19, signal recognition particle 19 kDa                                                CAA31280            PSFEp758E0317   no                                                               41,156                
  6888                  TALDO1, transaldolase 1                                                                  AAB53943            PSFEp758B0711   partly, none                                                     40,040                D, 1
  6990                  TCTE1L, t-complex-associated-testis-expressed 1-like                                     AAA57444            PSFEp758D0814   no                                                               38,062                A, 3
  6993                  TCTEL1, t-complex-associated-testis-expressed 1-like 1                                   BAA09317            PSFEp758F1123   yes, none                                 [DQ000521](DQ000521)   13,719                A, 14
  7001                  PRDX2, peroxiredoxin 2                                                                   AAH03022            PSFEp250A042    yes, none                                 [DQ000546](DQ000546)   24,815                C, 30
  7178                  TPT1, tumor protein, translationally-controlled 1                                        CAA34200            PSFEp250G011    yes, none                                 [DQ000539](DQ000539)   22,518                C, 14
  7247                  TSN, translin                                                                            CAA55341            PSFEp250B111    yes, none                                 [DQ000538](DQ000538)   29,106                C, 12
  7353                  UFD1L, ubiquitin fusion degradation 1-like                                               N P_005650          PSFEp758G0123   yes, none                                 [DQ000519](DQ000519)   41,777                D, 9
  7390                  UROS, uroporphyrinogen III synthase                                                      AAA60273            PSFEp758G0323   no                                                               29,894                D, 11
  7518                  XRCC4, X-ray repair complementing defective repair in Chinese hamster cells 4            AAH16314            PSFEp250A033    partly, none                                                     41,211                D, 26
  7531                  YWHAE, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon   AAH01440            PSFEp250H041    yes, A146G                                [DQ000541](DQ000541)   32,097                C, 24
  8125                  ANP32A, acidic (leucine-rich) nuclear phosphoprotein 32 family, member A                 AAB91548            PSFEp250D092    yes, none                                 [DQ000553](DQ000553)   31,509                D, 22
  8214                  DGCR6, DiGeorge syndrome critical region gene 6                                          CAA65339            PSFEp758G0324   yes, none                                 [DQ000533](DQ000533)   12,111                E, 19
  8407                  TAGLN2, transgelin 2                                                                     BAA04802            PSFEp250F062    yes, none                                 [DQ000550](DQ000550)   25,314                C, 27
  8544                  PIR, pirin                                                                               CAA69195            PSFEp758A0213   yes, none                                 [DQ000498](DQ000498)   34,613                C, 1
  8575                  PRKRA, protein kinase, interferon-inducible double stranded RNA dependent activator      CAB66550            PSFEp250D014    yes, none                                 [DQ000578](DQ000578)   37,328                E, 9
  8677                  STX10, syntaxin 10                                                                       AAC05087            PSFEp250D102    yes, none                                 [DQ000552](DQ000552)   25,369                D, 18
  8724                  SNX3, sorting nexin 3                                                                    AAC16040            PSFEp758A0323   yes, none                                 [DQ000514](DQ000514)   20,029                B, 15
  8896                  G10, maternal G10 transcript                                                             AAH22821            PSFEp250F011    yes, A394G                                [DQ000536](DQ000536)   19,766                C, 16
  8926                  SNURF, SNRPN upstream reading frame                                                      AAD31391            PSFEp250A0610   no                                                               11,334                C, 25
  9049                  AIP, aryl hydrocarbon receptor interacting protein                                       AAB59004            PSFEp758F1024   yes, none                                 [DQ000528](DQ000528)   40,589                A, 21
  9158                  FIBP, fibroblast growth factor (acidic) intracellular binding protein                    CAG33030            PSFEp250B022    partly, T602C                                                    44,803                C, 20
  9168                  TMSB10, thymosin, beta 10                                                                AAB25225            PSFEp758A0124   yes, none                                 [DQ000522](DQ000522)   6,292                 A, 18
  9337                  CNOT8, CCR4-NOT transcription complex, subunit 8                                         AAH17366            PSFEp758E0524   yes, none                                 [DQ000523](DQ000523)   36,354                A, 24
  9453                  GGPS1, geranylgeranyl diphosphate synthase 1                                             AAH05252            PSFEp250E052    partly, none                                                     37,795                D, 23
  9465                  AKAP7, A kinase (PRKA) anchor protein 7                                                  AAC39715            PSFEp758E0415   no                                                               34,000                A, 1
  9796                  PHYHIP, phytanoyl-CoA hydroxylase interacting protein                                    BAA13402            PSFEp758C1124   yes, T806C                                [DQ000530](DQ000530)   40,497                A, 29
  10000                 AKT3, v-akt murine thymoma viral oncogene homolog 3                                      CAB55977            PSFEp250B063    yes, none                                                        56,516                E, 20
  10063                 COX17, COX17 homolog, cytochrome c oxidase assembly protein (yeast)                      AAA98114            PSFEp758D0723   yes, none                                 [DQ000516](DQ000516)   8,182                 B, 3
  10094                 ARPC3, actin related protein 2/3 complex, subunit 3                                      AAB64191            PSFEp758G0811   yes, none                                 [DQ000507](DQ000507)   23,047                D, 7
  10169                 SERF2, small EDRK-rich factor 2                                                          AAC63516            PSFEp250A057    no                                                               9,821                 C, 23
  10228                 STX6, syntaxin 6                                                                         AAH09944            PSFEp758G0526   yes, none                                 [DQ000509](DQ000509)   32,100                B, 7
  10247                 HRSP12, heat-responsive protein 12 (14.5 kDa translational inhibitor protein, p14.5)     CAA64670            PSFEp758H0822   yes, none                                 [DQ000518](DQ000518)   15,760                D, 12
  10290                 APEG1, aortic preferentially expressed protein 1                                         AAH06346            PSFEp250B082    yes, none                                 [DQ000543](DQ000543)   15,614                E, 18
  10539                 TXNL2, thioredoxin-like 2                                                                AAH05289            PSFEp250A022    partly, none                                                     40,357                C, 26
  10588                 MTHFS, 5,10-methenyltetrahydrofolate synthetase                                          AAC41945            PSFEp758B0824   no                                                               24,522                D, 15
  10589                 DRAP1, DR1-associated protein 1 (negative cofactor 2 alpha)                              AAH10025            PSFEp250C042    yes, none                                 [DQ000542](DQ000542)   25,273                E, 3
  10598                 AHSA1, AHA1, activator of heat shock 90 kDa protein ATPase homolog 1 (yeast)             AAD09623            PSFEp250B091    no                                                               41,199                C, 15
  10606                 PAICS, phosphoribosylaminoimidazole carboxylase                                          AAH19255            PSFEp758G0226   partly, none                                                     50,005                A, 5
  10842                 C7orf16, chromosome 7 open reading frame 16                                              AAF03537            PSFEp758F0923   no                                                               19,132                B, 2
  10856                 RUVBL2, RuvB-like 2 (E. coli)                                                            AAH04531            PSFEp250C072    partly, none                                                     54,083                D, 25
  10912                 GADD45G, growth arrest and DNA-damage-inducible, gamma                                   AAC83329            PSFEp758F0111   yes, none                                 [DQ000504](DQ000504)   19,621                C, 4
  10933                 MORF4L1, mortality factor 4 like 1                                                       AAH22845            PSFEp250G051    partly, none                                                     40,155                C, 10
  10963                 STIP1, stress-induced-phosphoprotein 1                                                   AAA58682            PSFEp250A012    partly, A86C                                                     65,566                C, 28
  11140                 CDC37, CDC37 cell division cycle 37 homolog (S. cerevisiae)                              AAH08793            PSFEp250E042    partly, none                                                     47,394                D, 28
  11316                 COPE, coatomer protein complex, subunit epsilon                                          AAH07250            PSFEp758G1126   yes, none                                 [DQ000510](DQ000510)   37,406                B, 9
  11333                 PDAP1, PDGFA associated protein 1                                                        AAH07873            PSFEp250A073    yes, none                                 [DQ000554](DQ000554)   23,553                D, 30
  11337                 GABARAP, GABA(A) receptor-associated protein                                             AAD02337            PSFEp758H0922   no                                                               15,185                D, 10
  11344                 PTK9L, PTK9L protein tyrosine kinase 9-like (A6-related protein)                         N P_009215          PSFEp758A0127   yes, none                                 [DQ000525](DQ000525)   42,473                E, 13
  22818                 COPZ1, coatomer protein complex, subunit zeta 1                                          AAD34115            PSFEp758A0812   yes, none                                 [DQ000497](DQ000497)   22,698                D, 3
  22919                 MAPRE1, microtubule-associated protein, RP/EB family, member 1                           CAB53072            PSFEp250C112    yes, none                                 [DQ000557](DQ000557)   32,923                D, 21
  22931                 RAB18, RAB18, member RAS oncogene family                                                 CAB66668            PSFEp250C118    no                                                               25,900                B, 27
  23589                 CARHSP1, calcium regulated heat stable protein 1                                         AAD25021            PSFEp778D072    no                                                               40,934                
  25842                 ASF1A, ASF1 anti-silencing function 1 homolog A (S. cerevisiae)                          AAD34093            PSFEp758E1224   yes, none                                 [DQ000532](DQ000532)   25,891                E, 17
  25843                 PREI3, preimplantation protein 3                                                         AAD34090            PSFEp758B0812   yes, none                                 [DQ000500](DQ000500)   28,532                C, 2
  25996                 DKFZP566E144, small fragment nuclease                                                    AAD34109            PSFEp758G0423   yes, none                                 [DQ000520](DQ000520)   25,021                D, 13
  26289                 AK5, adenylate kinase 5                                                                  AAH12467            PSFEp250G042    yes, 3 bp insertion at 3\' end            [DQ000558](DQ000558)   24,897                E, 14
  26353                 HSPB8, heat shock 22 kDa protein 8                                                       CAB66870            PSFEp250G125    yes, none                                 [DQ000565](DQ000565)   24,527                B, 16
  27095                 TRAPPC3, trafficking protein particle complex 3                                          AAB96936            PSFEp758A0513   yes, none                                 [DQ000502](DQ000502)   22,774                C, 3
  27249                 C2orf25, chromosome 2 open reading frame 25                                              AAD20048            PSFEp758D1124   no                                                               35,864                A, 22
  27335                 eIF3k, eukaryotic translation initiation factor 3 subunit 12                             BAA76626            PSFEp758D0923   no                                                               26,326                D, 8
  27430                 MAT2B, methionine adenosyltransferase II, beta                                           CAB66599            PSFEp250A114    yes, none                                 [DQ000575](DQ000575)   40,476                B, 21
  28970                 PTD012, PTD012                                                                           CAB66540            PSFEp250B014    yes, none                                 [DQ000586](DQ000586)   38,042                E, 24
  29789                 PTD004, GTP-binding protein PTD004                                                       CAB66481            PSFEp250H073    yes, none                                 [DQ000564](DQ000564)   47,609                B, 18
  30819                 KCNIP2, Kv channel interacting protein 2                                                 CAB66656            PSFEp250G064    yes, none                                 [DQ000562](DQ000562)   28,964                E, 5
  51001                 CGI-12, CGI-12                                                                           AAH12995            PSFEp250B092    yes, none                                 [DQ000545](DQ000545)   40,832                C, 8
  51076                 CUTC, cutC copper transporter homolog (E. coli), CGI-32                                  AAH21105            PSFEp758E1112   yes, none                                 [DQ000505](DQ000505)   31,811                C, 5
  51078                 THAP4, THAP domain containing 4                                                          AAD27745            PSFEp250H116    no                                                               21,550                C, 7
  51155                 HN1, hematological and neurological expressed 1                                          AAH01420            PSFEp758G0126   yes, 3 bp deletion at 5\' end, G457A      [DQ000508](DQ000508)   18,937                C, 6
  51160                 VPS28, vacuolar protein sorting 28 (yeast)                                               AAF00499            PSFEp758C0323   yes, none                                 [DQ000513](DQ000513)   26,692                B, 14
  51335                 NEUGRIN, mesenchymal stem cell protein DSC92                                             CAD39160            PSFEp250B084    yes, none                                 [DQ000566](DQ000566)   27,342                B, 28
  51397                 COMMD10, COMM domain containing 10                                                       AAD44489            PSFEp758H0811   yes, none                                 [DQ000506](DQ000506)   25,466                D, 5
  51433                 ANAPC5, anaphase promoting complex subunit 5                                             BAA76629            PSFEp758E0214   no                                                               47,174                B, 8
  51451                 LCMT1, leucine carboxyl methyltransferase 1                                              AAH01214            PSFEp758H0126   partly, none                                                     41,303                B, 11
  51534                 C6orf55, chromosome 6 open reading frame 55                                              AAF76210            PSFEp758H0426   partly, none                                                     41,303                B, 13
  51629                 CGI-69, CGI-69                                                                           AAD34064            PSFEp758D0316   no                                                               63,564                B, 6
  51678                 MPP6, membrane protein, palmitoylated 6                                                  CAB66770            PSFEp250E023    yes, none                                 [DQ000583](DQ000583)   64,044                E, 27
  54816                 SUHW4, suppressor of hairy wing homolog 4 (Drosophila)                                   CAB66569            PSFEp250G074    yes, none                                 [DQ000587](DQ000587)   27,032                E, 22
  55255                 WDR41, WD repeat domain 41                                                               CAD38853            PSFEp250E105    yes, none                                 [DQ000563](DQ000563)   26,313                
  55276                 PGM2, phosphoglucomutase 2                                                               CAB66640            PSFEp250B113    partly, none                                                     71,239                B, 26
  56681                 SARA1, SAR1a gene homolog 1 (S. cerevisiae)                                              CAB66658            PSFEp250G115    yes, none                                 [DQ000570](DQ000570)   25,290                B, 17
  56911                 C21orf7, chromosome 21 open reading frame 7                                              CAD28500            PSFEp250B086    yes, none                                 [DQ000571](DQ000571)   19,032                E, 6
  57019                 LOC57019, cytokine induced apoptosis inhibitor 1                                         AAC24311            PSFEp758E0424   yes, none                                 [DQ000534](DQ000534)   36,506                E, 21
  58485                 TRAPPC1, trafficking protein particle complex 1                                          AAD44697            PSFEp250D071    yes, T350C                                [DQ000537](DQ000537)   19,754                E, 1
  64284                 RAB17, RAB17, member RAS oncogene family                                                 CAB66580            PSFEp250E095    yes, none                                 [DQ000572](DQ000572)   26,398                A, 6
  79632                 C6orf60, chromosome 6 open reading frame 60                                              CAB66701            PSFEp250B044    yes, none                                 [DQ000568](DQ000568)   34,217                B, 20
  79666                 PLEKHF2, pleckstrin homology domain containing, family F member 2                        CAD39132            PSFEp250D054    yes, A271G                                [DQ000581](DQ000581)   30,721                A, 9
  79791                 FBXO31, F-box protein 31                                                                 CAB66696            PSFEp250F085    yes, none                                 [DQ000585](DQ000585)   18,588                E, 12
  80347                 COASY, Coenzyme A synthase                                                               AAF87955            PSFEp250A053    yes, none                                 [DQ000551](DQ000551)   33,147                C, 29
  80895                 ILKAP, integrin-linked kinase-associated serine/threonine phosphatase 2C                 CAB66784            PSFEp250D083    yes, none                                 [DQ000569](DQ000569)   45,832                B, 19
  81876                 RAB1B, RAB1B, member RAS oncogene family                                                 CAB66570            PSFEp250C128    no                                                               25,094                A, 12
  81889                 DKFZP566J2046, fumarylacetoacetate hydrolase domain containing 1                         CAB66654            PSFEp250B074    yes, none                                 [DQ000567](DQ000567)   27,766                B, 24
  83538                 DKFZP434H0115, hypothetical protein DKFZp434H0115                                        CAB66694            PSFEp250G093    partly, none                                                     79,584                E, 11
  83543                 C9orf58, chromosome 9 open reading frame 58                                              CAB66501            PSFEp250B085    yes, none                                 [DQ000573](DQ000573)   19,990                B, 25
  83667                 SESN2, sestrin 2                                                                         CAB66486            PSFEp250F043    yes, none                                 [DQ000576](DQ000576)   57,420                E, 7
  84072                 NOHMA, HORMA domain containing protein                                                   CAB66689            PSFEp250F083    yes, none                                 [DQ000561](DQ000561)   47,343                E, 4
  84324                 CIP29, cytokine induced protein 29 kDa                                                   CAC37950            PSFEp758H1026   yes, none                                 [DQ000512](DQ000512)   26,594                A, 2
  84457                 PHYHIPL, phytanoyl-CoA hydroxylase interacting protein-like                              CAD39006            PSFEp250A084    yes, none                                 [DQ000579](DQ000579)   45,425                E, 10
  84557                 MAP1LC3A, microtubule-associated protein 1 light chain 3 alpha                           CAD38714            PSFEp250E106    yes, none                                 [DQ000584](DQ000584)   17,194                E, 26
  91603                 MGC20398, hypothetical protein MGC20398                                                  BAB70992            PSFEp758H0526   yes, none                                 [DQ000511](DQ000511)   44,915                B, 10
  94240                 EPSTI1, epithelial stromal interaction 1 (breast)                                        CAD38599            PSFEp250C015    yes, none                                 [DQ000580](DQ000580)   25,527                A, 11
  112611                RWDD2, RWD domain containing 2                                                           CAB52345            PSFEp758A1024   partly, T709C                                                    35,159                B, 5
  118812                C10orf83, chromosome 10 open reading frame 83                                            CAD38849            PSFEp250H085    yes, none                                 [DQ000574](DQ000574)   19,158                B, 23
  122060                FLJ30046, hypothetical protein FLJ30046                                                  CAD38891            PSFEp250E015    yes, none                                 [DQ000577](DQ000577)   23,468                E, 8
  136319                MTPN, myotrophin                                                                         CAD38909            PSFEp250D016    yes, none                                 [DQ000582](DQ000582)   15,817                A, 7
  140856                C20orf79, chromosome 20 open reading frame 79                                            CAB56175            PSFEp758G0224   yes, G258T                                [DQ000527](DQ000527)   20,585                A, 19

Biophysical properties of proteins which could be expressed in soluble form in *E. coli*were compared against all tested proteins. We found no significant correlation between expression success and either protein length or mean net charge (data not shown). However, when analysing the mean hydrophobicity, we found that hydrophobic proteins are less likely to be expressed in soluble form. Only one of 139 well expressed proteins has a mean hydrophobicity of more than 0.2, while 8% of the other proteins are above this value. This group of proteins does not contain transmembrane helices according to TMHMM, and therefore may represent peripheral membrane proteins with hydrophobic surface regions.

The *E. coli*expression clones of the PSF are publicly available from the RZPD German Resource Center \[[@B44]\]. The Additional file [1](#S1){ref-type="supplementary-material"} is an XML list of these clones. It can be viewed in a web browser (Figure [3](#F3){ref-type="fig"}). The Additional file contains, for each clone:

![The supplementary XML Additional file [1](#S1){ref-type="supplementary-material"} file displayed in a web browser.](1475-2859-4-21-3){#F3}

• Gene ID and name,

• Accession number,

• Cloning details,

• Strain and vector,

• Expected sequence,

• Protein expression results,

• Sequence verification.

Solved structures
-----------------

As a result of the target selection and cloning described in this paper, ten novel X-ray structures of human proteins were determined (Table [3](#T3){ref-type="table"}). The structure of one protein, TRAPPC3/BET-3, was determined after protein expression in *S. cerevisae*, while the other proteins were produced in *E. coli*.

###### 

Novel human protein structures The structures of full length proteins solved by the Protein Structure Factory.

  **NCBI Entrez gene ID**   **Name**                                               **GenBank protein accession**   **PDB ID**   **Reference**
  ------------------------- ------------------------------------------------------ ------------------------------- ------------ ---------------
  5716                      Gankyrin                                               [AAH11960](AAH11960)            1QYM         \[55\]
  10290                     APEG1, aortic preferentially expressed protein 1       [AAH06346](AAH06346)            1U2H         
  81889                     Fumarylacetoacetate hydrolase family member FLJ36880   [CAB66654](CAB66654)            1SAW         \[56\]
  28970                     PTD012                                                 [CAB66540](CAB66540)            1XCR         
  10247                     14.5 kDa translational inhibitor protein, p14.5        [CAA64670](CAA64670)            1ONI         \[57\]
  27095                     BET3, trafficking protein particle subunit             [AAB96936](AAB96936)            1SZ7         \[58\]
  5184                      Peptidase D                                            [AAH28295](AAH28295)                         
  51076                     CutC copper transporter homolog, CGI-32                [AAH21105](AAH21105)                         
  122553                    TPC6                                                   [CAI46185](CAI46185)            2BJN         \[59\]
  6449                      Nicotinamide mononucleotide adenylyltransferase        [NP_003012](NP_003012)          1GZU         \[60\]

Discussion
==========

We describe here the strategies and experiments of our structural genomics project on human proteins. In addition to the expression of full length proteins, the Protein Structure Factory has also studied protein domains by NMR spectroscopy, which has been described elsewhere \[[@B45]-[@B47]\]. Our selection of full length target proteins was mainly determined by the availability of full length cDNA clones. In addition, biophysical and bioinformatical criteria were applied, leading to a biased selection of target proteins from the human proteome. Therefore, we expect that the percentage of proteins that we could express and purify in soluble form, 18%, is higher than it would be in a randomly selected set. The low proportion of successfully expressed proteins indicates that *E. coli*is not the appropriate expression host for many full length human proteins. High throughput protein expression in alternative system such as yeast \[[@B9]-[@B11]\] or insect cells/baculovirus \[[@B48]\] has been established and will lead to better success rates in future projects.

Generally, clones that did express a soluble protein were verified by DNA sequencing, while clones that did not express or expressed an insoluble product were usually not sequence verified. It cannot be ruled out that some of the unsuccessful clones contain sequence errors introduced during cloning. Since template cDNA clones of the IMAGE consortium with only partial sequence information were used for most cloning experiments, expression clones that were not sequence verified might represent splice variants or isoforms of the original target. The distribution of mean net charge and length was similar among successfully expressed and all proteins, while very hydrophobic proteins were generally not expressed well in our *E. coli*expression system.

Future efforts in structural genomics of mammalian proteins will benefit from a much better supply of full length cDNA clones. Clones prepared for protein expression by resource centres and commercial suppliers are becoming available now. With such resources, alternative target selection strategies will become feasible that will not be restricted by the availability of cDNA clones. Instead, all potential target proteins, including splice variants, could be clustered by similarity and the most suitable members of each cluster could be selected by appropriate criteria as outlined in the Background section.

In our approach, we have excluded certain types of proteins such as membrane proteins and very large proteins. A structural genomics approach that includes membrane proteins would require standard protocols to optimise expression conditions and detergents \[[@B49]\]. The best strategy to study large proteins is to divide them into domains and smaller regions. However, such smaller constructs usually have to be designed manually.

All clones listed in the supplementary file (Additional file [1](#S1){ref-type="supplementary-material"}) and Table [2](#T2){ref-type="table"} are available to the research community. Thereby we hope to facilitate further functional characterisation of this set of human proteins.

Materials and Methods
=====================

Cloning with restriction enzymes
--------------------------------

cDNA inserts were amplified by PCR primers carrying tails with *Bam*HI and *Not*I sites and cloned into the respective sites of one of the expression vectors pQTEV, pQStrep2 or pGEX-6p1. This had the drawback that the restriction sites chosen for cloning might occur in the insert. In such cases, compatible overhangs were produced by alternative enzymes or by the hetero-stagger cloning method \[[@B50]\]. Alternative enzymes are *Bgl*II for *Bam*HI and the type IIs enzymes *Bpi*I, *Eco*31I, *Esp*3I, which can replace both *Bam*HI and *Not*I. Type IIs enzymes cut outside their recognition sequence and can produce arbitrary overhangs.

PCR Primer design
-----------------

PCR primers with tails carrying restriction enzyme cleavage sites were designed automatically by a Perl program. The primer design program adjusts the length of the primers to achieve a melting temperature close to a common default. Then, restriction enzymes that do not cut within the respective cDNA sequence are selected by the program and restriction enzyme sites are attached to the primer sequences. Finally, since restriction enzymes do not cut well at the very end of a DNA molecule, an additional short nucleotide tail is automatically attached to the primers. The sequence of this tail is optimised to minimise formation of secondary structure, hairpins or dimerisation. A Java version of the primer design software, \'ORFprimer\', is publicly available \[[@B51]\].

Automated high-throughput cloning, protein expression and purification
----------------------------------------------------------------------

PCR primers and cDNA clones were delivered in 96-well microplate format. Upon delivery, plates with PCR primers and template clones were reformatted to obtain corresponding plate positions by a Zinsser Speedy pipetting robot. The PCR master mix (Roche Expand) and cDNA primers (10 μM stocks) were pipetted into a PCR microplate with a multichannel pipet. Template clone bacteria were added with a 96-pin steel replicating device from overnight cultures in microtitre plates. PCR product size and yield was determined by agarose gel electrophoresis and the software Phoretix 1D Quantifier (Nonlinear dynamics). PCR products were purified with magnetic beads on the pipetting robot with a system that has been developed at the Max Planck Institute of Molecular Genetics in collaboration with Bruker Daltonics (Bruker genopure kit). The correct restriction enzyme master mixes were automatically added and the digested fragments were purified again, analysed by agarose gel electrophoresis and quantified. The robot then adjusted DNA concentrations to a common default by dilution. Ligations were set up manually with a multichannel pipet, and SCS1 *E. coli*cells carrying pRARE were transformed in a PCR microplate by chemical transformation on a PCR machine \[[@B52]\]. Transformed cells were manually plated on individual agar plates. Four clones were picked per transformation and were checked by PCR using vector primers. *E. coli*expression clones were ready for protein expression at this stage.

Primer sequences and template clones for cloning of the target cDNAs are listed in the supplementary XML file, Additional file [1](#S1){ref-type="supplementary-material"}.

The characterisation of expression clones by parallel expression and protein purification is described in reference \[[@B43]\].

Sequence analysis
-----------------

Sequence analysis software was run with default settings unless indicated otherwise. The mean charge of a protein was calculated as the difference of the number of positive and negatively charged amino acids (Lys, Arg and Glu, Asp, respectively) divided by the protein length. The mean hydrophobicity was calculated with the Kyte and Doolittle hydropathy index \[[@B53]\], obtained from the EMBOSS package \[[@B54]\]. The index values were added up for a given protein and divided by the protein length.
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Supplementary Material
======================

###### Additional File 1

A ZIP archive that contains the XML list psfClones.xml of PSF clones available at the RZPD and the XSL stylesheet psfToHtml.xsl to display the XML file in a web browser. The two files should be extracted from the ZIP archive into a local directory. Then psfClones.xml can be opened with a current web browser like Mozilla or Internet Explorer. 1414 Clones for 537 target proteins are described in the XML file. It lists the gene, cloning details, expected sequence, protein expression results and the degree of sequence verification for each clone.

###### 

Click here for file
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